News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Synerx Pharma Announces Approval for Ciclopirox Topical 8% Solution



9/19/2007 1:01:00 PM

NEWTOWN, Pa.--(BUSINESS WIRE)--Synerx Pharma, LLC announced today that it has received final U.S. Food and Drug Administration (FDA) approval for the Company’s Abbreviated New Drug Application (ANDA) for Ciclopirox topical solution, 8%. Synerx’s product is a generic equivalent of Dermik Laboratories’ prescription product Penlac®, a topical ciclopirox treatment for nail fungus. Sales of Penlac® in the U.S. exceeded $85 million in 2006.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES